Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease

François‐Xavier Danlos, Anne-Laure Voisin, Valérie Dyevre, +18

European Journal of Cancer

Anti-programmed Death 1Inflammatory DiseaseAutoimmune DiseaseMedicinePre-existing Autoimmune +11

Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score)

Frédéric Bigot, Eduardo Castañón, Capucine Baldini, +15

European Journal of Cancer

Prognostic EvaluationAutoimmune DiseaseImmunotherapy PhaseImmunodeficienciesPrognosis +8

Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma

C. Owen, Xue Bai, Serigne Lo, +32

Annals of Oncology

Tumor ImmunologyMelanomaImmunologyImmune Checkpoint InhibitorAutoimmunity +4

Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation

Marie-Léa Gauci, Émilie Lanoy, Stéphane Champiat, +16

Clinical Cancer Research

Pharmacological sensitivity of ATP release triggered by photoliberation of inositol‐1,4,5‐trisphosphate and zero extracellular calcium in brain endothelial cells

Katleen Braet, Sandrine Aspeslagh, Wouter Vandamme, +4

Journal of Cellular Physiology

Galactose‐modified iNKT cell agonists stabilized by an induced fit of CD1d prevent tumour metastasis

Sandrine Aspeslagh, Yali Li, Esther Dawen Yu, +13

The EMBO Journal

Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study

Guillaume Manson, Alexandre Maria, F. Poizeau, +29

Journal for ImmunoTherapy of Cancer

Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade

Carlos Gomez‐Roca, Philippe A. Cassier, Dmitriy Zamarin, +26

Journal for ImmunoTherapy of Cancer

Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis

Evandro de Azambuja, Mariana Brandão, Hans Wildiers, +47

ESMO Open

Tumor PD-L1 status and CD8+ tumor-infiltrating T cells: markers of improved prognosis in oropharyngeal cancer

Astrid De Meulenaere, Tijl Vermassen, Sandrine Aspeslagh, +6

Oncotarget